SS Innovations reports preliminary Q4 2025 revenue of $15 million

SS Innovations International Inc. (NASDAQ: SSII) announced preliminary unaudited revenue of approximately $15.0 million for the fourth quarter of 2025, representing an 85% increase from $8.1 million in the same period of 2024.

The surgical robotics company reported 37 SSi Mantra system installations in the fourth quarter, up 68% from 22 installations in the prior year quarter. For the full year 2025, the company expects revenue of approximately $43.0 million, up 108% from $20.6 million in 2024.

Annual SSi Mantra installations totaled 103 units in 2025, compared to 47 installations in 2024, marking a 119% increase. The cumulative installed base reached 168 systems as of December 31, 2025, up from 65 systems at the end of 2024.

Dr. Sudhir Srivastava, Chairman and Chief Executive Officer, stated that the company anticipates FDA completion of its 510(k) premarket notification review for the SSi Mantra in the first half of 2026. The company also continues pursuing European Union CE marking certification, which it believes it can obtain in the first half of 2026.

SS Innovations plans to report complete fourth quarter and full year 2025 financial results before the end of February. The company noted that the preliminary results are unaudited and subject to completion of quarter-end financial and accounting procedures.

The Fort Lauderdale-based company develops surgical robotic technologies and operates primarily in India. Its SSi Mantra system has been clinically validated in India across more than 100 different types of surgical procedures.

You May Also Be Interested In

• SEALSQ posts 131% revenue gain in H1 2026, net loss widens
• LPA gets Peru antitrust approval for $145M logistics park sale
• Cosmos Health unit secures 2.5M-unit drug manufacturing deal with Viofar